RET and non-small cell lung carcinoma: Considering the attention paid towards combination therapy in NSCLC instead, Fujimura searched for a compatible agent that could be used in a mixture with alectinib, a small molecule agent with RET kinase inhibitory activity, to enhance its antitumor effects [79].